ImmuPharma plc (LON:IMM – Get Free Report) was down 15.2% on Thursday . The stock traded as low as GBX 2.30 ($0.03) and last traded at GBX 2.46 ($0.03). Approximately 4,418,779 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 24,563,990 shares. The stock had previously closed at GBX 2.90 ($0.04).
ImmuPharma Price Performance
The firm has a market cap of £10.79 million, a price-to-earnings ratio of -259.00 and a beta of 1.53. The business has a 50-day moving average of GBX 1.54 and a 200-day moving average of GBX 1.68.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- How to Short a Stock in 5 Easy Steps
- 3 Cheap Small-Cap Banks for Dividend Growth Investors
- How to Calculate Options Profits
- 3 Defensive Stocks Analysts Are Bullish on to Kick Off the Year
- Where Do I Find 52-Week Highs and Lows?
- Vistra Corp: Could 2025 Continue Its Streak of Outperformance?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
